Defiance Nasdaq Junior Biotechnology ETF
IBBJ
NASDAQ Global Market- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- DE United States of America
- IPO Date
- Aug 3, 2020
- CIK
- 0001540305
- Similar Companies
- Business
- Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is an exchange-traded fund that seeks to track the total return performance, before fees and expenses, of the Nasdaq Junior Biotechnology Index, providing investors with targeted exposure to small- and mid-cap biotechnology and pharmaceutical companies listed on Nasdaq with market capitalizations generally below $5 billion. The fund holds a diversified portfolio of Nasdaq-listed stocks, including American Depositary Receipts, focused on biotechnology and pharmaceuticals as classified by the Industry Classification Benchmark; key sectors include genomics, DNA technology, genetic engineering, molecular biology, and prescription or over-the-counter drug manufacturing. IBBJ employs a market-cap weighted strategy with an 8% cap on the largest five holdings and semi-annual rebalancing and reconstitution, emphasizing junior disruptors in the healthcare sector for potential innovation and merger-and-acquisition activity. Launched on August 4, 2020, and listed on NYSE Arca, the ETF is issued and managed by Defiance ETFs LLC, a thematic ETF sponsor founded in 2018 and headquartered in New York. Defiance ETFs oversees approximately 200 holdings in the Nasdaq Junior Biotechnology Index, with recent assets under management around $2.54 million, an expense ratio of 0.45%, and operations domiciled in the United States targeting global investors seeking sector-specific equity exposure in the blended development stage of biotechnology. The fund distributes qualified dividends, with a reported annual yield of about 1.00%, and maintains geographic concentration primarily in North America (99.95% of assets). In recent developments, Defiance ETFs has expanded its product suite beyond IBBJ, launching innovative single-stock leveraged ETFs including the Defiance Daily Target 2X Short BMNR ETF (BMNZ) in November 2025 and long-exposure funds in October 2025, reflecting a strategic shift toward amplified tactical trading instruments for high-growth companies without requiring margin accounts. These launches build on Defiance's focus on thematic and leveraged strategies, positioning IBBJ within a broader lineup that empowers sophisticated investors amid ongoing biotech sector dynamics, such as heightened M&A activity involving junior firms. No major acquisitions, funding rounds, or reorganizations specific to IBBJ have been reported in the last 1-2 years, though the underlying index benefits from persistent innovation and consolidation trends in small-cap biotech.